Biodegradable Polymers in Drug Delivery

Biodegradable Polymers in Clinical Use and Clinical Development

Volumn , Issue , 2011, Pages 1-58

  Jain, Jay Prakash ^a   Yenet Ayen, Wubeante ^a   Domb, Abraham J ^b   Kumar, Neeraj ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Biodegradable polymers in drug delivery considered "green" and as "polymer therapeutics"; Biodegradation patterns, degradation products generated, with no adverse effect at site of use; Polymer selection for biomedical application and toxicological profiles, polymers classes with key features

Indexed keywords

EID: 84876729958     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118015810.ch1     Document Type: Chapter

References (374)

1. Gunatillake, P., R. Mayadunne, and R. Adhikari. Recent developments in biodegradable synthetic polymers. Biotechnol. Annu. Rev. 2006;12:301-347.
2. Pachence, J.M., M.P. Bohrer, J. Kohn, L. Robert, and V. Joseph. Biodegradable polymers. In Principles of Tissue Engineering, 3rd ed. Academic: Burlington, 2007, pp. 323-339.
3. Scott, G. "Green" polymers. Polym. Degrad. Stab. 2000;68(1):1-7.
4. Tuzlakoglu, K. and R.L. Reis. Biodegradable polymeric fiber structures in tissue engineering. Tissue Eng. Part B Rev. 2009;15(1):17-27.
5. Chiellini, F., A.M. Piras, C. Errico, and E. Chiellini. Micro/nanostructured polymeric systems for biomedical and pharmaceutical applications. Nanomed, 2008;3(3):367-393.
6. Heller, J. Biodegradable polymers in controlled drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1984;1(1):39-90.
7. Ratcliffe, A. Tissue engineering of vascular grafts. Matrix Biol. 2000;19 (4):353-357.
8. Ju, X.J., R. Xie, L. Yang, and L.Y. Chu. Biodegradable "intelligent" materials in response to physical stimuli for biomedical applications. Expert Opin. Ther. Pat. 2009;19(4):493-507.
9. Gunja, N.J. and K.A. Athanasiou. Biodegradable materials in arthroscopy. Sports Med. Arthrosc. 2006;14(3):112-119.
10. Chitkara, D., A. Shikanov, N. Kumar, and A.J. Domb. Biodegradable injectable in situ depot-forming drug delivery systems. Macromol. Biosci. 2006;6(12):977-990.
11. Commandeur, S., H.M. van Beusekom, and W.J. van der Giessen. Polymers, drug release, and drug-eluting stents.J. Interv. Cardiol. 2006;19(6):500-506.
12. Friedman, J.A., A.J. Windebank, M.J. Moore, R.J. Spinner, B.L. Currier, and M.J. Yaszemski. Biodegradable polymer grafts for surgical repair of the injured spinal cord. Neurosurgery 2002;51(3):742-751; discussion 751-752.
13. Piskin, E. Biodegradable polymeric matrices for bioartificial implants. Int.J. Artif. Organs 2002;25(5):434-440.
14. Gaspar, R.S. and R. Duncan. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 2009;61(13):1220-1231.
15. Kiick, K.L. Materials science. Polymer therapeutics. Science 2007;317(5842):1182-1183.
16. Benagiano, G., H. Gabelnick, and M. Farris. Contraceptive devices: Subcutaneous delivery systems. Expert Rev. Med. Devices 2008;5(5):623-637.
17. Dash, A.K. and G.C. Cudworth II. Therapeutic applications of implantable drug delivery systems.J. Pharmacol. Toxicol. Methods. 1998;40(1):1-12.
18. Nair, L.S. and C.T. Laurencin. Biodegradable polymers as biomaterials. Prog. Polym. Sci. 2007;32(8-9):762-798.
19. Malafaya, P.B., G.A. Silva, and R.L. Reis. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv. Drug Deliv. Rev. 2007;59(4-5):207-233.
20. Dang, J.M. and K.W. Leong. Natural polymers for gene delivery and tissue engineering. Adv. Drug Deliv. Rev. 2006;58(4):487-499.
21. Stacey, M. In Natural & Synthetic Polymers an Introduction, Vol. 17.H. I. Bolker (ed.). Marcel Dekker: New York, 1976, pp. 456-456.
22. Reinert, K.H., J.P. Carbone, J. Sven Erik, and F. Brian. Synthetic polymers. In Encyclopedia of Ecology. Academic: Oxford, 2008, pp. 3461-3472.
23. Thompson, H. Biomaterials: We have the technology. 2005 (cited September 2009); available from: http://www.devicelink.com/mddi/archive/05/05/024.html.
24. Schlechter, M. Biodegradable polymers (PLS025B). 2005 (cited September 2009); available from: http://www.bccresearch.com/report/PLS025B.html.
25. Navarro, M., A. Michiardi, O. Castano, and J.A. Planell. Biomaterials in orthopaedics.J. R. Soc. Interface 2008;5(27):1137-1158.
26. Holland, T.A. and A.G. Mikos. Biodegradable polymeric scaffolds. Improvements in bone tissue engineering through controlled drug delivery. Adv. Biochem. Eng. Biotechnol. 2006;102:161-185.
27. Liu, X. and P.X. Ma. Polymeric scaffolds for bone tissue engineering. Ann. Biomed. Eng. 2004;32(3):477-486.
28. Borenstein, J.T., G. Yogesh, T. Osamu, and Z. Hans. Tissue engineering. In Comprehensive Microsystems. 2008, Elsevier: Oxford, 2008, pp. 541-583.
29. Carlos Rodríguez-Cabello, J., J. Reguera, A. Girotti, M. Alonso, and A.M. Testera. Developing functionality in elastin-like polymers by increasing their molecular complexity: The power of the genetic engineering approach. Prog. Polym. Sci. 2005;30(11):1119-1145.
30. El-Amin, S.F., H.H. Lu, Y. Khan, J. Burems, J. Mitchell, R.S. Tuan, and C.T. Laurencin. Extracellular matrix production by human osteoblasts cultured on biodegradable polymers applicable for tissue engineering. Biomaterials 2003;24(7): 1213-1221.
31. Ma, P.X. Biomimetic materials for tissue engineering. Adv. Drug Deliv. Rev. 2008;60(2):184-198.
32. Pěgo, A.P., A.A. Poot, D.W. Grijpma, and J. Feijen. Biodegradable elastomeric scaffolds for soft tissue engineering.J. Control. Release 2003;87(1-3):69-79.
33. Sheridan, M.H., L.D. Shea, M.C. Peters, and D.J. Mooney. Bioabsorbable polymer scaffolds for tissue engineering capable of sustained growth factor delivery.J. Control. Release 2000;64(1-3):91-102.
34. van Dijkhuizen-Radersma, R., L. Moroni, A.v. Apeldoorn, Z. Zhang, D. Grijpma, B. Clemens van, T. Peter, L. Anders, H. Jeffrey, F.W. David, C. Ranieri, D.d. B. Joost, and S. Jé rǒ me. Degradable polymers for tissue engineering. In Tissue Engineering. Academic: Burlington, 2008, pp. 193-221.
35. Gomes, M., H. Azevedo, P. Malafaya, S. Silva, J. Oliveira, G. Silva, R. Sousa, J. Mano, R. Reis, B. Clemens van, T. Peter, L. Anders, H. Jeffrey, F.W. David, C. Ranieri, D.d. B. Joost, and S. Jé rǒ me. Natural polymers in tissue engineering applications. In Tissue Engineering. Academic: Burlington, 2008, pp. 145-192.
36. Lee, S.-H. and H. Shin. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv. Drug Deliv. Rev. 2007;59(4-5):339-359.
37. Malafaya, P.B., G.A. Silva, and R.L. Reis. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv. Drug Deliv. Rev. 2007;59(4-5):207-233.
38. Deng, J.S., L. Li, Y. Tian, M. Meisters, H.C. Chang, D. Stephens, S. Chen, and D. Robinson. The relationship between structures and in vitro properties of a polyanhydride implant containing gentamicin sulfate. Pharm. Dev. Technol. 2001;6 (4):541-549.
39. Dittrich, M., P. Solich, L. Opletal, A.J. Hunt, and J.D. Smart. 20-Hydroxyecdysone release from biodegradable devices: The effect of size and shape. Drug Dev. Ind. Pharm. 2000;26(12):1285-1291.
40. Park, E.-S., M. Maniar, and J. Shah. Water uptake in to polyanhydride devices: Kinetics of uptake and effects of model compounds incorporated, and device geometry on water uptake.J. Control. Release 1996;40(1-2):55-65.
41. Ju, X.J., R. Xie, L. Yang, and L.Y. Chu. Biodegradable "intelligent" materials in response to chemical stimuli for biomedical applications. Expert Opin. Ther. Pat. 2009;19(5):683-696.
42. Bawa, P., V. Pillay, Y.E. Choonara, and L.C. du Toit. Stimuli-responsive polymers and their applications in drug delivery. Biomed. Mater. 2009;4(2):22001.
43. Meng, F., Z. Zhong, and J. Feijen, Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009;10(2):197-209.
44. Onaca, O., R. Enea, D.W. Hughes, and W. Meier. Stimuli-responsive polymersomes as nanocarriers for drug and gene delivery. Macromol. Biosci. 2009;9(2): 129-139.
45. Mendes, P.M. Stimuli-responsive surfaces for bio-applications. Chem. Soc. Rev. 2008;37(11):2512-2529.
46. Stoop, R. Smart biomaterials for tissue engineering of cartilage. Injury 2008;39 (Suppl 1):S77-87.
47. Dayananda, K., C. He, D.K. Park, T.G. Park, and D.S. Lee. pH-and temperature-sensitive multiblock copolymer hydrogels composed of poly(ethylene glycol) and poly(amino urethane). Polymer 2008;49(23):4968-4973.
48. Qiu, Y. and K. Park. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. Rev. 2001;53(3):321-339.
49. Sershen, S. and J. West, Implantable, polymeric systems for modulated drug delivery. Adv. Drug Deliv. Rev. 2002;54(9):1225-1235.
50. Iconomopoulou, S.M., J.K. Kallitsis, and G.A. Voyiatzis. Incorporation of small molecular weight active agents into polymeric components. Recent Pat. Drug Deliv. Formul. 2008;2(2):94-107.
51. Jain, J.P., S. Modi, A.J. Domb, and N. Kumar. Role of polyanhydrides as localized drug carriers.J. Control. Release 2005;103(3):541-563.
52. Park, J.H., M. Ye, and K. Park. Biodegradable polymers for microencapsulation of drugs. Molecules 2005;10(1):146-161.
53. Gopferich, A. and J. Tessmar. Polyanhydride degradation and erosion. Adv. Drug Deliv. Rev. 2002;54(7):911-931.
54. Jain, J.P., D. Chitkara, and N. Kumar. Polyanhydrides as localized drug delivery carrier: An update. Expert Opin. Drug Deliv. 2008;5(8):889-907.
55. Tamada, J. and R. Langer. The development of polyanhydrides for drug delivery applications.J. Biomater. Sci. Polym. Ed. 1992;3(4):315-353.
56. Bala, I., S. Hariharan, and M.N. Kumar. PLGA nanoparticles in drug delivery: The state of the art. Crit. Rev. Ther. Drug Carrier Syst. 2004;21(5): 387-422.
57. Campolongo, M.J. and D. Luo. Drug delivery: Old polymer learns new tracts. Nat. Mater. 2009;8(6):447-448.
58. Dhiman, N., M. Dutta, and G.K. Khuller. Poly (DL-lactide-co-glycolide) based delivery systems for vaccines and drugs. Indian J. Exp. Biol. 2000;38(8):746-752.
59. Jain, R., N.H. Shah, A.W. Malick, and C.T. Rhodes. Controlled drug delivery by biodegradable poly(ester) devices: Different preparative approaches. Drug Dev. Ind. Pharm. 1998;24(8):703-727.
60. Jain, R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21(23):2475-2490.
61. Mundargi, R.C., V.R. Babu, V. Rangaswamy, P. Patel, and T.M. Aminabhavi. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives.J. Control. Release 2008;125(3):193-209.
62. Vert, M. Aliphatic polyesters: Great degradable polymers that cannot do everything. Biomacromolecules 2005;6(2):538-546.
63. Coombes, A.G., S.C. Rizzi, M. Williamson, J.E. Barralet, S. Downes, and W.A. Wallace. Precipitation casting of polycaprolactone for applications in tissue engineering and drug delivery. Biomaterials 2004;25(2):315-325.
64. Dhanaraju, M.D., D. Gopinath, M.R. Ahmed, R. Jayakumar, and C. Vamsadhara. Characterization of polymeric poly(e-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids.J. Biomed. Mater. Res. A 2006;76(1):63-72.
65. Huatan, H., J.H. Collett, D. Attwood, and C. Booth. Preparation and characterization of poly(e-caprolactone) polymer blends for the delivery of proteins. Biomaterials 1995;16(17):1297-1303.
66. Jia, W., Y. Gu, M. Gou, M. Dai, X. Li, B. Kan, J. Yang, Q. Song, Y. Wei, and Z. Qian. Preparation of biodegradable polycaprolactone/poly(ethylene glycol)/ polycaprolactone (PCEC) nanoparticles. Drug Deliv. 2008;15(7):409-416.
67. Juni, K. and M. Nakano. Poly(hydroxy acids) in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1987;3(3):209-232.
68. Luciani, A., V. Coccoli, S. Orsi, L. Ambrosio, and P.A. Netti. PCL microspheres based functional scaffolds by bottom-up approach with predefined microstructural properties and release profiles. Biomaterials 2008;29(36):4800-4807.
69. Mei, L., H. Sun, and C. Song. Local delivery of modified paclitaxel-loaded poly(e-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia.J. Pharm. Sci. 2009;98(6):2040-2050.
70. Sheikh, F.A., N.A. Barakat, M.A. Kanjwal, S. Aryal, M.S. Khil, and H.Y. Kim. Novel self-assembled amphiphilic poly(e-caprolactone)-grafted-poly(vinyl alcohol) nanoparticles: Hydrophobic and hydrophilic drugs carrier nanoparticles.J. Mater. Sci. Mater. Med. 2009;20(3):821-831.
71. Zhu, K.J., Y. Li, H.L. Jiang, H. Yasuda, A. Ichimaru, K. Yamamoto, P. Lecomte, and R. Jerome. Preparation, characterization and in vitro release properties of ibuprofen-loaded microspheres based on polylactide, poly(e-caprolactone) and their copolymers.J. Microencapsul. 2005;22(1):25-36.
72. Ashammakhi, N. and P. Rokkanen. Absorbable polyglycolide devices in trauma and bone surgery. Biomaterials 1997;18(1):3-9.
73. Hutmacher, D., M.B. Hurzeler, and H. Schliephake. A review of material properties of biodegradable and bioresorbable polymers and devices for GTR and GBR applications. Int.J. Oral. Maxillofac. Implants 1996;11(5): 667-678.
74. Lu, J.M., X. Wang, C. Marin-Muller, H. Wang, P.H. Lin, Q. Yao, and C. Chen. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 2009;9(4):325-341.
75. Miller, N.D. and D.F. Williams. The in vivo and in vitro degradation of poly (glycolic acid) suture material as a function of applied strain. Biomaterials 1984;5 (6):365-368.
76. Pulapura, S. and J. Kohn. Trends in the development of bioresorbable polymers for medical applications.J. Biomater. Appl. 1992;6(3):216-250.
77. Shum, A.W. T. and A.F. T. Mak. Morphological and biomechanical characterization of poly(glycolic acid) scaffolds after in vitro degradation. Polym. Degrad. Stab. 2003;81(1):141-149.
78. Gupta, B., N. Revagade, and J. Hilborn. Poly(lactic acid) fiber: An overview. Prog. Polym. Sci. 2007;32(4):455-482.
79. Hyon, S.H., Biodegradable poly(lactic acid) microspheres for drug delivery systems. Yonsei Med.J. 2000;41(6):720-734.
80. Miyajima, M., A. Koshika, J.I. Okada, and M. Ikeda. Mechanism of drug release from poly(-lactic acid) matrix containing acidic or neutral drugs.J. Control. Release 1999;60(2-3):199-209.
81. Saulnier, B., S. Ponsart, J. Coudane, H. Garreau, and M. Vert. Lactic acid-based functionalized polymers via copolymerization and chemical modification. Macromol. Biosci. 2004;4(3):232-237.
82. Steendam, R., M.J. van Steenbergen, W.E. Hennink, H.W. Frijlink, and C.F. Lerk. Effect of molecular weight and glass transition on relaxation and release behaviour of poly(-lactic acid) tablets.J. Control. Release 2001;70(1-2):71-82.
83. Tsuji, H. Poly(lactide) stereocomplexes: Formation, structure, properties, degradation, and applications. Macromol. Biosci. 2005;5(7):569-597.
84. Wang, S., W. Cui, and J. Bei. Bulk and surface modifications of polylactide. Anal. Bioanal. Chem. 2005;381(3):547-556.
85. Barham, P.J., P. Barker, and S.J. Organ. Physical properties of poly(hydroxybutyrate) and copolymers of hydroxybutyrate and hydroxyvalerate. FEMS Microbiol. Lett. 1992;103(2-4):289-298.
86. Chen, C., C.H. Yu, Y.C. Cheng, P.H. F. Yu, and M.K. Cheung. Biodegradable nanoparticles of amphiphilic triblock copolymers based on poly(3-hydroxybutyrate) and poly(ethylene glycol) as drug carriers. Biomaterials 2006;27(27):4804-4814.
87. Martin, D.P. and S.F. Williams. Medical applications of poly-4-hydroxybutyrate: A strong flexible absorbable biomaterial. Biochem. Eng.J. 2003;16(2):97-105.
88. Pouton, C.W. and S. Akhtar. Biosynthetic polyhydroxyalkanoates and their potential in drug delivery. Adv. Drug Deliv. Rev. 1996;18(2):133-162.
89. van der Walle, G.A., G.J. de Koning, R.A. Weusthuis, and G. Eggink. Properties, modifications and applications of biopolyesters. Adv. Biochem. Eng. Biotechnol. 2001;71:263-291.
90. Cai, Z.-Y., D.-A. Yang, N. Zhang, C.-G. Ji, L. Zhu, and T. Zhang. Poly(propylene fumarate)/(calcium sulphate/[ß]-tricalcium phosphate) composites: Preparation, characterization and in vitro degradation. Acta Biomater. 2009;5(2):628-635.
91. Fisher, J.P., D. Dean, and A.G. Mikos. Photocrosslinking characteristics and mechanical properties of diethyl fumarate/poly(propylene fumarate) biomaterials. Biomaterials 2002;23(22):4333-4343.
92. Haesslein, A., H. Ueda, M.C. Hacker, S. Jo, D.M. Ammon, R.N. Borazjani, J.F. Kunzler, J.C. Salamone, and A.G. Mikos. Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers.J. Control. Release 2006;114(2):251-260.
93. He, S., M.J. Yaszemski, A.W. Yasko, P.S. Engel, and A.G. Mikos. Injectable biodegradable polymer composites based on poly(propylene fumarate) crosslinked with poly(ethylene glycol)-dimethacrylate. Biomaterials 2000;21(23): 2389-2394.
94. Jayabalan, M., K.T. Shalumon, and M.K. Mitha. Injectable biomaterials for minimally invasive orthopedic treatments.J. Mater. Sci. Mater. Med. 2009;20 (6):1379-1387.
95. Kempen, D.H., L. Lu, C. Kim, X. Zhu, W.J. Dhert, B.L. Currier, and M.J. Yaszemski. Controlled drug release from a novel injectable biodegradable microsphere/scaffold composite based on poly(propylene fumarate).J. Biomed. Mater. Res. A 2006;77(1):103-111.
96. Kim, C.W., R. Talac, L. Lu, M.J. Moore, B.L. Currier, and M.J. Yaszemski. Characterization of porous injectable poly-(propylene fumarate)-based bone graft substitute.J. Biomed. Mater. Res. A 2008;85(4):1114-1119.
97. Mistry, A.S., Q.P. Pham, C. Schouten, T. Yeh, E.M. Christenson, A.G. Mikos, and J.A. Jansen. In vivo bone biocompatibility and degradation of porous fumarate-based polymer/alumoxane nanocomposites for bone tissue engineering.J. Biomed. Mater. Res. A 2009;92(2):451-462.
98. Wang, S., L. Lu, and M.J. Yaszemski. Bone-tissue-engineering material poly (propylene fumarate): Correlation between molecular weight, chain dimensions, and physical properties. Biomacromolecules 2006;7(6):1976-1982.
99. Yaszemski, M.J., R.G. Payne, W.C. Hayes, R. Langer, and A.G. Mikos. In vitro degradation of a poly(propylene fumarate)-based composite material. Biomaterials 1996;17(22):2127-2130.
100. Bai, W., D. Chen, Z. Zhang, Q. Li, D. Zhang, and C. Xiong. Poly(paradioxanone)/ inorganic particle composites as a novel biomaterial.J. Biomed. Mater. Res. B Appl. Biomater. 2009;90(2):945-951.
101. Hutmacher, D.W., J.C. Goh, and S.H. Teoh, An introduction to biodegradable materials for tissue engineering applications. Ann. Acad. Med. Singapore 2001;30 (2):183-191.
102. Li, M.-X., R.-X. Zhuo, and F.-Q. Qu. Study on the preparation of novel functional poly(dioxanone) and for the controlled release of protein. React. Funct. Polym. 2003;55(2):185-195.
103. Lin, H.L., C.C. Chu, and D. Grubb. Hydrolytic degradation and morphologic study of poly-p-dioxanone.J. Biomed. Mater. Res. 1993;27(2):153-166.
104. Saito, N., N. Murakami, J. Takahashi, H. Horiuchi, H. Ota, H. Kato, T. Okada, K. Nozaki, and K. Takaoka. Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv. Drug Deliv. Rev. 2005;57 (7):1037-1048.
105. Song, C.X., X.M. Cui, and A. Schindler. Biodegradable copolymers based on pdioxanone for medical application. Med. Biol. Eng. Comput. 1993;31(Suppl): S147-151.
106. Vogt, S., S. Berger, I. Wilke, Y. Larcher, J. Weisser, and M. Schnabelrauch. Design of oligolactone-based scaffolds for bone tissue engineering. Biomed. Mater. Eng. 2005;15(1-2):73-85.
107. Wang, X.-L., K.-K. Yang, Y.-Z. Wang, D.-Y. Wang, and Z. Yang. Crystallization and morphology of a novel biodegradable polymer system: Poly(1,4-dioxan-2-one)/starch blends. Acta Mater. 2004;52(16):4899-4905.
108. Kluin, O.S., H.C. van der Mei, H.J. Busscher, and D. Neut. A surface-eroding antibiotic delivery system based on poly-(trimethylene carbonate). Biomaterials 2009;30(27):4738-4742.
109. Papenburg, B.J., S. Schüller-Ravoo, L.A. M. Bolhuis-Versteeg, L. Hartsuiker, D.W. Grijpma, J. Feijen, M. Wessling, and D. Stamatialis. Designing porosity and topography of poly(1,3-trimethylene carbonate) scaffolds. Acta Biomater. 2009;5(9): 3281-3294.
110. Timbart, L., M.Y. Tse, S.C. Pang, O. Babasola, and B.G. Amsden. Low viscosity poly(trimethylene carbonate) for localized drug delivery: Rheological properties and in vivo degradation. Macromol. Biosci. 2009;9(8):786-794.
111. Zhang, Z., D.W. Grijpma, and J. Feijen. Trimethylene carbonate-based polymers for controlled drug delivery applications.J. Control. Release 2006;116(2): e28-e29.
112. Zhang, Z., R. Kuijer, S.K. Bulstra, D.W. Grijpma, and J. Feijen. The in vivo and in vitro degradation behavior of poly(trimethylene carbonate). Biomaterials 2006;27(9):1741-1748.
113. Zurita, R., L. Franco, J. Puiggalí, and A. Rodríguez-Galá n. The hydrolytic degradation of a segmented glycolide-trimethylene carbonate copolymer (Maxon (TM)). Polym. Degrad. Stab. 2007;92(6):975-985.
114. Andriano, K.P., Y. Tabata, Y. Ikada, and J. Heller. In vitro and in vivo comparison of bulk and surface hsydrolysis in absorbable polymer scaffolds for tissue engineering.J. Biomed. Mater. Res. 1999;48(5):602-612.
115. Barr, J., K.W. Woodburn, S.Y. Ng, H.-R. Shen, and J. Heller. Post surgical pain management with poly(ortho esters). Adv. Drug Deliv. Rev. 2002;54(7): 1041-1048.
116. Chia, H.H., Y.Y. Yang, T.S. Chung, S. Ng, and J. Heller. Auto-catalyzed poly (ortho ester) microspheres: A study of their erosion and drug release mechanism.J. Control. Release 2001;75(1-2):11-25.
117. Einmahl, S., S. Capancioni, K. Schwach-Abdellaoui, M. Moeller, F. Behar-Cohen, and R. Gurny. Therapeutic applications of viscous and injectable poly(ortho esters). Adv. Drug Deliv. Rev. 2001;53(1):45-73.
118. Heller, J. Development of poly(ortho esters): A historical overview. Biomaterials 1990;11(9):659-665.
119. Heller, J. Development of poly(ortho esters): A historical overview. Biomaterials 1990;11(9):659-665.
120. Heller, J. and J. Barr. Biochronomer technology. Expert Opin. Drug Deliv. 2005;2 (1):169-183.
121. Heller, J., J. Barr, S. Ng, H.-R. Shen, R. Gurny, K. Schwach-Abdelaoui, A. Rothen-Weinhold, and M. van de Weert. Development of poly(ortho esters) and their application for bovine serum albumin and bupivacaine delivery.J. Control. Release 2002;78(1-3):133-141.
122. Heller, J., J. Barr, S.Y. Ng, K.S. Abdellauoi, and R. Gurny. Poly(ortho esters): Synthesis, characterization, properties and uses. Adv. Drug Deliv. Rev. 2002;54 (7):1015-1039.
123. Heller, J., J. Barr, S.Y. Ng, H.R. Shen, K. Schwach-Abdellaoui, S. Einmahl, A. Rothen-Weinhold, and R. Gurny. Poly(ortho esters)-their development and some recent applications. Eur.J. Pharm. Biopharm. 2000;50(1):121-128.
124. Heller, J. and K.J. Himmelstein, Poly(ortho ester) biodegradable polymer systems. Methods Enzymol. 1985;112:422-436.
125. Heller, J., Y.F. Maa, P. Wuthrich, S.Y. Ng, and R. Duncan. Recent developments in the synthesis and utilization of poly (ortho esters).J. Control. Release. 1991;16(1-2):3-13.
126. Merkli, A., J. Heller, C. Tabatabay, and R. Gurny. Synthesis and characterization of a new biodegradable semi-solid poly(ortho ester) for drug delivery systems.J. Biomater. Sci. Polym. Ed. 1993;4(5):505-516.
127. Shih, C., S. Lucas, and G.M. Zentner. Acid catalyzed poly(ortho ester) matrices for intermediate term drug delivery.J. Control. Release 1991;15(1):55-63.
128. Sintzel, M.B., J. Heller, S.Y. Ng, M.S. Taylor, C. Tabatabay, and R. Gurny. Synthesis and characterization of self-catalyzed poly(ortho ester). Biomaterials 1998;19(7-9):791-800.
129. Sintzel, M.B., A. Merkli, J. Heller, C. Tabatabay, and R. Gurny. Synthesis and analysis of viscous poly(ortho-ester) analogs for controlled drug release. Int.J. Pharm. 1997;155(2):263-269.
130. Tang, R., R.N. Palumbo, W. Ji, and C. Wang. Poly(ortho ester amides): Acidlabile temperature-responsive copolymers for potential biomedical applications. Biomacromolecules 2009;10(4):722-777.
131. van de Weert, M., M.J. van Steenbergen, J.L. Cleland, J. Heller, W.E. Hennink, and D.J. Crommelin. Semisolid, self-catalyzed poly(ortho ester)s as controlledrelease systems: Protein release and protein stability issues.J. Pharm. Sci. 2002;91 (4):1065-1074.
132. Wang, C., Q. Ge, D. Ting, D. Nguyen, H.R. Shen, J. Chen, H.N. Eisen, J. Heller, R. Langer, and D. Putnam. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat. Mater. 2004;3(3):190-196.
133. Yu, J., Z. Lu, H. Zheng, and R. Zhuo. Synthesis and characterization of new ointment-like poly(ortho esters). Eur. Polym.J. 2002;38(5):971-975.
134. Alla, A., A. Rodríguez-Galá n, A. Martínez de Llarduya, and S. Muñoz-Guerra. Degradable poly(ester amide)s based on L-tartaric acid. Polymer 1997;38 (19):4935-4944.
135. Armelin, E., N. Paracuellos, A. Rodríguez-Galá n, and J. Puiggalí. Study on the degradability of poly(ester amide)s derived from the a-amino acids glycine, and -alanine containing a variable amide/ester ratio. Polymer 2001;42(19):7923-7932.
136. Bettinger, C.J., J.P. Bruggeman, J.T. Borenstein, and R.S. Langer. Amino alcohol-based degradable poly(ester amide) elastomers. Biomaterials 2008;29 (15):2315-2325.
137. Edlund, U. and A.C. Albertsson. Polyesters based on diacid monomers. Adv. Drug Deliv. Rev. 2003;55(4):585-609.
138. Guo, K. and C.-C. Chu. Biodegradation of unsaturated poly(ester-amide)s and their hydrogels. Biomaterials 2007;28(22):3284-3294.
139. Yamanouchi, D., J. Wu, A.N. Lazar, K. Craig Kent, C.-C. Chu, and B. Liu. Biodegradable arginine-based poly(ester-amide)s as non-viral gene delivery reagents. Biomaterials 2008;29(22):3269-3277.
140. Yeol Lee, S., J.W. Park, Y.T. Yoo, and S.S. Im. Hydrolytic degradation behaviour and microstructural changes of poly(ester-co-amide)s. Polym. Degrad. Stab. 2002;78(1):63-71.
141. Dahiyat, B.I., E.M. Posadas, S. Hirosue, E. Hostin, and K.W. Leong. Degradable biomaterials with elastomeric characteristics and drug-carrier function. React. Polym. 1995;25(2-3):101-109.
142. Dahiyat, B.I., M. Richards, and K.W. Leong. Controlled release from poly (phosphoester) matrices.J. Control. Release 1995;33(1):13-21.
143. Koseva, N., A. Bogomilova, K. Atkova, and K. Troev. New functional polyphosphoesters: Design and characterization. React. Funct. Polym. 2008;68(5): 954-966.
144. Li, Q., J. Wang, S. Shahani, D.D. N. Sun, B. Sharma, J.H. Elisseeff, and K.W. Leong. Biodegradable and photocrosslinkable polyphosphoester hydrogel. Biomaterials 2006;27(7):1027-1034.
145. Mao, H.Q. and K.W. Leong. Design of polyphosphoester-DNA nanoparticles for non-viral gene delivery. Adv. Genet. 2005;53:275-306.
146. Wang, S., A.C. Wan, X. Xu, S. Gao, H.Q. Mao, K.W. Leong, and H. Yu. A new nerve guide conduit material composed of a biodegradable poly(phosphoester). Biomaterials 2001;22(10):1157-1169.
147. Zhao, Z., J. Wang, H.-Q. Mao, and K.W. Leong. Polyphosphoesters in drug and gene delivery. Adv. Drug Deliv. Rev. 2003;55(4):483-499.
148. Chaubal, M.V., A.S. Gupta, S.T. Lopina, and D.F. Bruley. Polyphosphates and other phosphorus-containing polymers for drug delivery applications. Crit. Rev. Ther. Drug Carrier Syst. 2003;20(4):295-315.
149. Crommen, J., J. Vandorpe, and E. Schacht. Degradable polyphosphazenes for biomedical applications.J. Control. Release 1993;24(1-3):167-180.
150. Gunatillake, P.A. and R. Adhikari. Biodegradable synthetic polymers for tissue engineering. Eur. Cell Mater. 2003;5:1-16; discussion 16.
151. Lakshmi, S., D.S. Katti, and C.T. Laurencin. Biodegradable polyphosphazenes for drug delivery applications. Adv. Drug Deliv. Rev. 2003;55(4):467-482.
152. Lora, S., G. Palma, R. Bozio, P. Caliceti, and G. Pezzin. Polyphosphazenes as biomaterials: Surface modification of poly(bis(trifluoroethoxy)phosphazene) with polyethylene glycols. Biomaterials 1993;14(6):430-436.
153. Potin, P. and R. De Jaeger. Polyphosphazenes: Synthesis, structures, properties, applications. Eur. Polym.J. 1991;27(4-5):341-348.
154. Bourke, S.L. and J. Kohn. Polymers derived from the amino acid-tyrosine: Polycarbonates, polyarylates and copolymers with poly(ethylene glycol). Adv. Drug Deliv. Rev. 2003;55(4):447-466.
155. Deming, T.J. Synthetic polypeptides for biomedical applications. Prog. Polym. Sci. 2007;32(8-9):858-875.
156. Katchalski, E., J.T. E.M. L. Anson, and B. Kenneth. Poly-a-amino acids. In Advances in Protein Chemistry. Academic: New York, 1951, pp. 123-185.
157. Lavasanifar, A., J. Samuel, and G.S. Kwon. Poly(ethylene oxide)-blockpoly(-amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 2002;54(2): 169-190.
158. Sela, M., E. Katchalski, J.M. L.A. K.B. C.B. Anfinsen, and T.E. John. Biological properties of poly-a-amino acids. In Advances in Protein Chemistry. Academic: New York, 1959, pp. 391-478.
159. Kumar, N., R.S. Langer, and A.J. Domb. Polyanhydrides: An overview. Adv. Drug Deliv. Rev. 2002;54(7):889-910.
160. Domb, A. Synthesis and characterization of biodegradable aromatic anhydride copolymers. Macromolecules 1992;25(1):12-17.
161. Kim, M.S., K.S. Seo, H.S. Seong, S.H. Cho, H.B. Lee, K.D. Hong, S.K. Kim, and G. Khang. Synthesis and characterization of polyanhydride for local BCNU delivery carriers. Biomed. Mater. Eng. 2005;15(3):229-238.
162. Lesniak, M.S., U. Upadhyay, R. Goodwin, B. Tyler, and H. Brem. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 2005;25(6B):3825-3831.
163. Domb, A.J. and M. Maniar. Absorbable biopolymers derived from dimer fatty acids.J. Polym. Sci: Part A: Polym. Chem. 1993;31(5):1275-1285.
164. Domb, A.J. and M. Maniar. Fatty Acid Terminated Polyanhydride. 1994; US Patent 5317079.
165. Domb, A.J. and R. Nudelman, Biodegradable polymers derived from natural fatty acids.J. Polym. Sci. Part A: Polym. Chem. 1995;33(4):717-725.
166. Jain, J.P., S. Modi, and N. Kumar. Hydroxy fatty acid based polyanhydride as drug delivery system: Synthesis, characterization, in vitro degradation, drug release, and biocompatibility.J. Biomed. Mater. Res. A 2007;84(3):740-752.
167. Jain, J.P., M. Sokolsky, N. Kumar, and A.J. Domb. Fatty acid based biodegradable polymer. Polym. Rev. 2008;48(1):156-191.
168. Kumar, N., M. Krishnan, T. Azzam, A. Magora, M.N. V. Ravikumar, D.R. Flanagan, and A.J. Domb. Analysis of fatty acid anhydrides and polyanhydrides. Anal. Chim. Acta 2002;465(1-2):257-272.
169. Teomim, D. and A.J. Domb. Fatty acid terminated polyanhydrides.J. Poly. Sci. Part A: Polym. Chem. 1999;37(16):3337-3344.
170. Teomim, D., A. Nyska, and A.J. Domb. Ricinoleic acid-based biopolymers.J. Biomed. Mater. Res. 1999;45(3):258-267.
171. Arias, J.L., M.A. Ruiz, M. Ló pez-Viota, and Á.V. Delgado. Poly(alkylcyanoacrylate) colloidal particles as vehicles for antitumour drug delivery: A comparative study. Colloids Surf. B 2008;62(1):64-70.
172. Graf, A., A. McDowell, and T. Rades. Poly(alkylcyanoacrylate) nanoparticles for enhanced delivery of therapeutics-Is there real potential? Expert Opin. Drug Deliv. 2009;6(4):371-387.
173. Vauthier, C., C. Dubernet, E. Fattal, H. Pinto-Alphandary, and P. Couvreur. Poly (alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 2003;55(4):519-548.
174. Vauthier, C., D. Labarre, and G. Ponchel, Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery.J. Drug Target. 2007;15(10):641-663.
175. Alves, C.M., Y. Yang, D.L. Carnes, J.L. Ong, V.L. Sylvia, D.D. Dean, C.M. Agrawal, and R.L. Reis. Modulating bone cells response onto starch-based biomaterials by surface plasma treatment and protein adsorption. Biomaterials 2007;28(2):307-315.
176. Azevedo, H.S., F.M. Gama, and R.L. Reis. In vitro assessment of the enzymatic degradation of several starch based biomaterials. Biomacromolecules 2003;4 (6):1703-1712.
177. Cascone, M.G., N. Barbani, C. Cristallini, P. Giusti, G. Ciardelli, and L. Lazzeri. Bioartificial polymeric materials based on polysaccharides.J. Biomater. Sci. Polym. Ed. 2001;12(3):267-281.
178. Chandra, R. and R. Rustgi. Biodegradable polymers. Prog. Polym. Sci. 1998;23:1273-1335.
179. Elvira, C., J.F. Mano, J. San Roman, and R.L. Reis. Starch-based biodegradable hydrogels with potential biomedical applications as drug delivery systems. Biomaterials 2002;23(9):1955-1966.
180. Gomes, M.E., A.S. Ribeiro, P.B. Malafaya, R.L. Reis, and A.M. Cunha. A new approach based on injection moulding to produce biodegradable starch-based polymeric scaffolds: Morphology, mechanical and degradation behaviour. Biomaterials 2001;22(9):883-889.
181. Marques, A.P., R.L. Reis, and J.A. Hunt. The biocompatibility of novel starchbased polymers and composites: In vitro studies. Biomaterials 2002;23 (6):1471-1478.
182. Mayer, J.M., G.R. Elion, C.M. Buchanan, B.K. Sullivan, S.D. Pratt, and D.L. Kaplan. Biodegradable blends of cellulose acetate and starch: Production and properties.J. Macromol. Sci. Pure Appl. Chem. 1995;32(4):775-785.
183. Czaja, W.K., D.J. Young, M. Kawecki, and R.M. Brown. The future prospects of microbial cellulose in biomedical applications. Biomacromolecules 2007; 8(1):1-12.
184. Fricain, J.C., P.L. Granja, M.A. Barbosa, B. de Jé so, N. Barthe, and C. Baquey. Cellulose phosphates as biomaterials. In vivo biocompatibility studies. Biomaterials 2002;23(4):971-980.
185. Klemm, D., B. Heublein, H.P. Fink, and A. Bohn. Cellulose: Fascinating biopolymer and sustainable raw material. Angew. Chem. Int. Ed. Engl. 2005;44 (22):3358-3393.
186. Müller, F.A., L. Müller, I. Hofmann, P. Greil, M.M. Wenzel, and R. Staudenmaier. Cellulose-based scaffold materials for cartilage tissue engineering. Biomaterials 2006;27(21):3955-3963.
187. Prabaharan, M. and J.F. Mano. Stimuli-responsive hydrogels based on polysaccharides incorporated with thermo-responsive polymers as novel biomaterials. Macromol. Biosci. 2006;6(12):991-1008.
188. Svensson, A., E. Nicklasson, T. Harrah, B. Panilaitis, D.L. Kaplan, M. Brittberg, and P. Gatenholm. Bacterial cellulose as a potential scaffold for tissue engineering of cartilage. Biomaterials 2005;26(4):419-431.
189. Thomas, S., A review of the physical, biological and clinical properties of a bacterial cellulose wound dressing.J. Wound Care 2008;17(8):349-352.
190. Alves, N.M. and J.F. Mano. Chitosan derivatives obtained by chemical modifications for biomedical and environmental applications. Int.J. Biol. Macromol. 2008;43(5):401-414.
191. Arca, H.C., M. Gunbeyaz, and S. Senel. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 2009;8(7):937-953.
192. Bowman, K. and K.W. Leong. Chitosan nanoparticles for oral drug and gene delivery. Int.J. Nanomed. 2006;1(2):117-128.
193. Jayakumar, R., N. Nwe, S. Tokura, and H. Tamura. Sulfated chitin and chitosan as novel biomaterials. Int.J. Biol. Macromol. 2007;40(3):175-181.
194. Jiang, T., S.G. Kumbar, L.S. Nair, and C.T. Laurencin. Biologically active chitosan systems for tissue engineering and regenerative medicine. Curr. Top. Med. Chem. 2008;8(4):354-364.
195. Khor, E. and L.Y. Lim. Implantable applications of chitin and chitosan. Biomaterials 2003;24(13):2339-2349.
196. Kim, I.Y., S.J. Seo, H.S. Moon, M.K. Yoo, I.Y. Park, B.C. Kim, and C.S. Cho. Chitosan and its derivatives for tissue engineering applications. Biotechnol. Adv. 2008;26(1):1-21.
197. Kumar, M.N., R.A. Muzzarelli, C. Muzzarelli, H. Sashiwa, and A.J. Domb. Chitosan chemistry and pharmaceutical perspectives. Chem. Rev. 2004;104 (12):6017-6084.
198. Masotti, A. and G. Ortaggi. Chitosan micro-and nanospheres: Fabrication and applications for drug and DNA delivery. Mini. Rev. Med. Chem. 2009;9 (4):463-469.
199. Mourya, V.K. and N.N. Inamdar. Trimethyl chitosan and its applications in drug delivery.J. Mater. Sci. Mater. Med. 2009;20(5):1057-1079.
200. Panos, I., N. Acosta, and A. Heras. New drug delivery systems based on chitosan. Curr. Drug Discov. Technol. 2008;5(4):333-341.
201. Prabaharan, M. Review paper: Chitosan derivatives as promising materials for controlled drug delivery.J. Biomater. Appl. 2008;23(1):5-36.
202. Shahidi, F. and R. Abuzaytoun. Chitin, chitosan, and co-products: Chemistry, production, applications, and health effects. Adv. Food Nutr. Res. 2005;49: 93-135.
203. Shi, C., Y. Zhu, X. Ran, M. Wang, Y. Su, and T. Cheng. Therapeutic potential of chitosan and its derivatives in regenerative medicine.J. Surg. Res. 2006;133 (2):185-192.
204. Vinsova, J. and E. Vavrikova. Recent advances in drugs and prodrugs design of chitosan. Curr. Pharm. Des. 2008;14(13):1311-1326.
205. Yilmaz, E. Chitosan: A versatile biomaterial. Adv. Exp. Med. Biol. 2004;553:59-68.
206. Hillier, K., M. Rakkar, S.J. Enna, and B.B. David. Alginic acid. In xPharm: The Comprehensive Pharmacology Reference. Elsevier: New York, 2007, pp. 1-3.
207. Draget, K.I., G. Skja°k Bræk, and O. Smidsrød. Alginic acid gels: The effect of alginate chemical composition and molecular weight. Carbohydr. Polym. 1994;25 (1):31-38.
208. Tonnesen, H.H. and J. Karlsen. Alginate in drug delivery systems. Drug Dev. Ind. Pharm. 2002;28(6):621-630.
209. Beasley, K.L., M.A. Weiss, and R.A. Weiss. Hyaluronic acid fillers: A comprehensive review. Facial Plast. Surg. 2009;25(2):86-94.
210. Brown, M.B. and S.A. Jones. Hyaluronic acid: A unique topical vehicle for the localized delivery of drugs to the skin.J. Eur. Acad. Dermatol. Venereol. 2005;19 (3):308-318.
211. Iavazzo, C., S. Athanasiou, E. Pitsouni, and M.E. Falagas. Hyaluronic acid: An effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur. Urol. 2007;51(6):1534-1540; discussion 1540-1541.
212. Kogan, G., L. Soltes, R. Stern, and P. Gemeiner. Hyaluronic acid: A natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol. Lett. 2007;29(1):17-25.
213. Liao, Y.H., S.A. Jones, B. Forbes, G.P. Martin, and M.B. Brown. Hyaluronan: Pharmaceutical characterization and drug delivery. Drug Deliv. 2005;12 (6):327-342.
214. Migliore, A. and M. Granata. Intra-articular use of hyaluronic acid in the treatment of osteoarthritis. Clin. Interv. Aging 2008;3(2):365-369.
215. Price, R.D., M.G. Berry, and H.A. Navsaria. Hyaluronic acid: The scientific and clinical evidence.J. Plast. Reconstr. Aesthet. Surg. 2007;60(10):1110-1119.
216. Volpi, N., J. Schiller, R. Stern, and L. Soltes. Role, metabolism, chemical modifications and applications of hyaluronan. Curr. Med. Chem. 2009;16 (14):1718-1745.
217. Yadav, A.K., P. Mishra, and G.P. Agrawal. An insight on hyaluronic acid in drug targeting and drug delivery.J. Drug. Target. 2008;16(2):91-107.
218. Chourasia, M.K. and S.K. Jain. Polysaccharides for colon targeted drug delivery. Drug Deliv. 2004;11(2):129-148.
219. Hennink, W.E., O. Franssen, W.N. E. van Dijk-Wolthuis, and H. Talsma. Dextran hydrogels for the controlled release of proteins.J. Control. Release 1997;48(2-3):107-114.
220. Larsen, C. Dextran prodrugs-Structure and stability in relation to therapeutic activity. Adv. Drug Deliv. Rev. 1989;3(1):103-154.
221. Mehvar, R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents.J. Control. Release 2000;69(1):1-25.
222. Van Tomme, S.R. and W.E. Hennink. Biodegradable dextran hydrogels for protein delivery applications. Expert Rev. Med. Devices 2007;4(2):147-164.
223. Bana, G., B. Jamard, E. Verrouil, and B. Mazieres. Chondroitin sulfate in the management of hip and knee osteoarthritis: An overview. Adv. Pharmacol. 2006;53:507-522.
224. Brandl, N., J. Holzmann, R. Schabus, and M. Huettinger. Effects of chondroitin sulfate on the cellular metabolism. Adv. Pharmacol. 2006;53:433-447.
225. Campo, G.M., A. Avenoso, S. Campo, A.M. Ferlazzo, and A. Calatroni. Antioxidant activity of chondroitin sulfate. Adv. Pharmacol. 2006;53:417-431.
226. Handley, C.J., T. Samiric, and M.Z. Ilic. Structure, metabolism, and tissue roles of chondroitin sulfate proteoglycans. Adv. Pharmacol. 2006;53:219-232.
227. Lamari, F.N. The potential of chondroitin sulfate as a therapeutic agent. Connect. Tissue Res. 2008;49(3):289-292.
228. Lauder, R.M. Chondroitin sulphate: A complex molecule with potential impacts on a wide range of biological systems. Complement. Ther. Med. 2009;17(1):56-62.
229. Morris, J.D. and K.M. Smith. Chondroitin sulfate in osteoarthritis therapy. Orthopedics 2009;32(4).
230. Yamada, S. and K. Sugahara. Potential therapeutic application of chondroitin sulfate/dermatan sulfate. Curr. Drug Discov. Technol. 2008;5(4):289-301.
231. Keppeler, S., A. Ellis, and J.C. Jacquier. Cross-linked carrageenan beads for controlled release delivery systems. Carbohydr. Polym. 2009;78(4):973-977.
232. Kranz, H., K. Jürgens, M. Pinier, and J. Siepmann. Drug release from MCC-and carrageenan-based pellets: Experiment and theory. Eur.J. Pharm. Biopharm. 2009;73(2):302-309.
233. Thomson, A.W. and E.F. Fowler. Carrageenan: A review of its effects on the immune system. Agents Actions 1981;11(3):265-273.
234. Valenta, C. The use of mucoadhesive polymers in vaginal delivery. Adv. Drug Deliv. Rev. 2005;57(11):1692-1712.
235. Ehrenfreund-Kleinman, T., T. Azzam, R. Falk, I. Polacheck, J. Golenser, and A.J. Domb. Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates. Biomaterials 2002;23(5):1327-1335.
236. Ehrenfreund-Kleinman, T., Z. Gazit, D. Gazit, T. Azzam, J. Golenser, and A.J. Domb. Synthesis and biodegradation of arabinogalactan sponges prepared by reductive amination. Biomaterials 2002;23(23):4621-4631.
237. Prescott, J.H., P. Enriquez, C. Jung, E. Menz, and E.V. Groman. Larch arabinogalactan for hepatic drug delivery: Isolation and characterization of a 9 kDa arabinogalactan fragment. Carbohydr. Res. 1995;278(1):113-128.
238. Seifert, G.J. and K. Roberts. The biology of arabinogalactan proteins. Annu. Rev. Plant Biol. 2007;58:137-161.
239. Chivers, R.A. In vitro tissue welding using albumin solder: Bond strengths and bonding temperatures. Int.J. Adhes. Adhes. 2000;20(3):179-187.
240. Chuang, V.T., U. Kragh-Hansen, and M. Otagiri. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002;19(5):569-577.
241. Gradishar, W.J. Albumin-bound paclitaxel: A next-generation taxane. Expert. Opin. Pharmacother. 2006;7(8):1041-1053.
242. Gupta, P.K. and C.T. Hung. Albumin microspheres. I: Physico-chemical characteristics.J. Microencapsul. 1989;6(4):427-462.
243. Gupta, P.K. and C.T. Hung. Albumin microspheres. II: Applications in drug delivery.J. Microencapsul. 1989;6(4):463-472.
244. Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles.J. Control. Release 2008;132(3):171-183.
245. Perez, E.A. Novel enhanced delivery taxanes: An update. Semin. Oncol. 2007;34(3) (suppl):1-5.
246. Abraham, L.C., E. Zuena, B. Perez-Ramirez, and D.L. Kaplan. Guide to collagen characterization for biomaterial studies.J. Biomed. Mater. Res. B Appl. Biomater. 2008;87(1):264-285.
247. Friess, W., Collagen-biomaterial for drug delivery. Eur.J. Pharm. Biopharm. 1998;45(2):113-136.
248. Lee, C.H., A. Singla, and Y. Lee. Biomedical applications of collagen. Int.J. Pharm. 2001;221(1-2):1-22.
249. Miyata, T., T. Taira, and Y. Noishiki, Collagen engineering for biomaterial use. Clin. Mater. 1992;9(3-4):139-148.
250. Olsen, D., C. Yang, M. Bodo, R. Chang, S. Leigh, J. Baez, D. Carmichael, M. Perala, E.R. Hamalainen, M. Jarvinen, and J. Polarek. Recombinant collagen and gelatin for drug delivery. Adv. Drug Deliv. Rev. 2003;55(12):1547-1567.
251. Paul, R.G. and A.J. Bailey. Chemical stabilisation of collagen as a biomimetic. Scient. World J.2003;3:138-155.
252. Rao, K.P., Recent developments of collagen-based materials for medical applications and drug delivery systems.J. Biomater. Sci. Polym. Ed. 1995;7(7):623-645.
253. Ruszczak, Z. and W. Friess. Collagen as a carrier for on-site delivery of antibacterial drugs. Adv. Drug Deliv. Rev. 2003;55(12):1679-1698.
254. Stenzel, K.H., T. Miyata, and A.L. Rubin. Collagen as a biomaterial. Annu. Rev. Biophys. Bioeng. 1974;3(0):231-253.
255. Stol, M., K. Smetana, P. Korbelá, and M. Adam. Poly(HEMA)-collagen composite as a biomaterial for hard tissue replacement. Clin. Mater. 1993;13(1-4):19-20.
256. Esposito, E., R. Cortesi, and C. Nastruzzi. Gelatin microspheres: Influence of preparation parameters and thermal treatment on chemico-physical and biopharmaceutical properties. Biomaterials 1996;17(20):2009-2020.
257. Sakai, S., K. Hirose, K. Taguchi, Y. Ogushi, and K. Kawakami. An injectable, in situ enzymatically gellable, gelatin derivative for drug delivery and tissue engineering. Biomaterials 2009;30(20):3371-3377.
258. Young, S., M. Wong, Y. Tabata, and A.G. Mikos. Gelatin as a delivery vehicle for the controlled release of bioactive molecules.J. Control. Release 2005;109 (1-3):256-274.
259. des Rieux, A., A. Shikanov, and L.D. Shea. Fibrin hydrogels for non-viral vector delivery in vitro.J. Control. Release 2009;136(2):148-154.
260. Eyrich, D., F. Brandl, B. Appel, H. Wiese, G. Maier, M. Wenzel, R. Staudenmaier, A. Goepferich, and T. Blunk. Long-term stable fibrin gels for cartilage engineering. Biomaterials 2007;28(1):55-65.
261. San-Galli, F., G. Deminiere, J. Gué rin, and M. Rabaud. Use of a biodegradable elastin-fibrin material, Neuroplasts, as a dural substitute. Biomaterials 1996;17 (11):1081-1085.
262. Silver, F.H., M.-C. Wang, and G.D. Pins. Preparation and use of fibrin glue in surgery. Biomaterials 1995;16(12):891-903.
263. Wozniak, G. Fibrin sealants in supporting surgical techniques: The importance of individual components. Cardiovas. Surg. 2003;11(Suppl 1):17-21.
264. Ijntema, K., W.J. M. Heuvelsland, C.A. M.C. Dirix, and A.P. Sam. Hydroxyapatite microcarriers for biocontrolled release of protein drugs. Int.J. Pharm. 1994;112(3):215-224.
265. Matsumoto, T., M. Okazaki, A. Nakahira, J. Sasaki, H. Egusa, and T. Sohmura. Modification of apatite materials for bone tissue engineering and drug delivery carriers. Curr. Med. Chem. 2007;14(25):2726-2733.
266. Paul, W. and C.P. Sharma. Ceramic drug delivery: A perspective.J. Biomater. Appl. 2003;17(4):253-264.
267. Sopyan, I., M. Mel, S. Ramesh, and K.A. Khalid. Porous hydroxyapatite for artificial bone applications. Sci. Technol. Adv. Mater. 2007;8(1-2):116-123.
268. Wahl, D.A. and J.T. Czernuszka. Collagen-hydroxyapatite composites for hard tissue repair. Eur. Cell Mater. 2006;11:43-56.
269. Yoshikawa, H. and A. Myoui. Bone tissue engineering with porous hydroxyapatite ceramics.J. Artif. Organs 2005;8(3):131-136.
270. Yoshikawa, H., N. Tamai, T. Murase, and A. Myoui. Interconnected porous hydroxyapatite ceramics for bone tissue engineering.J. Rog. Soc. Interface 2009;6 (Suppl 3):S341-348.
271. Tamada, J.A. and R. Langer, Erosion kinetics of hydrolytically degradable polymers. Proc. Natl. Acad. Sci.U. S.A. 1993;90(2):552-556.
272. Gopferich, A. Erosion of composite polymer matrices. Biomaterials 1997;8 (5):397-403.
273. Gopferich, A. and R. Langer. Modeling of polymer erosion. Macromolecules 1993;6:4105-4112.
274. Langer, R. Drug delivery and targeting. Nature 1998;392(6679 Suppl):5-10.
275. Langer, R., D. Lund, K. Leong, and J. Folkman. Controlled release of macromolecules: Biological studies.J. Control. Release 1985;2:331-341.
276. Mathiowitz, E., J.S. Jacob, Y.S. Jong, G.P. Carino, D.E. Chickering, P. Chaturvedi, C.A. Santos, K. Vijayaraghavan, S. Montgomery, M. Bassett, and C. Morrell. Biologically erodible microspheres as potential oral drug delivery systems. Nature 1997;386:410-414.
277. Gorna, K. and S. Gogolewski. In vitro degradation of novel medical biodegradable aliphatic polyurethanes based on e-caprolactone and Pluronicss with various hydrophilicities. Polym. Degrad. Stab. 2002;75(1):113-122.
278. Lao, L.L., S.S. Venkatraman, and N.A. Peppas. Modeling of drug release from biodegradable polymer blends. Eur.J. Pharma. Biopharm. 2008;70(3): 796-803.
279. Reed, A.M. and D.K. Gilding. Biodegradable polymers for use in surgery-poly (glycolic)/poly(Iactic acid) homo and copolymers: 2. In vitro degradation. Polymer 1981;22(4):494-498.
280. Barbanti, S.H., A.R. Santos, Jr., C.A. Zavaglia, and E.A. Duek. Porous and dense poly(L-lactic acid) and poly(D,L-lactic acid-co-glycolic acid) scaffolds: In vitro degradation in culture medium and osteoblasts culture.J. Mater. Sci. Mater. Med. 2004;15(12):1315-1321.
281. Djemai, A., L.F. Gladden, J. Booth, R.S. Kittlety, and P.R. Gellert. MRI investigation of hydration and heterogeneous degradation of aliphatic polyesters derived from lactic and glycolic acids: A controlled drug delivery device. Magn. Reson. Imaging 2001;19(3-4):521-523.
282. Li, S. and S. McCarthy. Further investigations on the hydrolytic degradation of poly (dl-lactide). Biomaterials 1999;20(1):35-44.
283. Siepmann, J., K. Elkharraz, F. Siepmann, and D. Klose. How autocatalysis accelerates drug release from PLGA-based microparticles: A quantitative treatment. Biomacromolecules 2005;6(4):2312-2319.
284. Wang, Z., S. Wang, R. Guidoin, Y. Marois, and Z. Zhang. In vitro homogeneous and heterogeneous degradation of poly(-caprolactone/polyethylene glycol/llactide): The absence of autocatalysis and the role of enzymes.J. Biomed. Mater. Res. A 2006;79(1):6-15.
285. Belbella, A., C. Vauthier, H. Fessi, J.-P. Devissaguet, and F. Puisieux. In vitro degradation of nanospheres from poly(d,l-lactides) of different molecular weights and polydispersities. Int.J. Pharm. 1996;129(1-2):95-102.
286. Braunecker, J., M. Baba, G.E. Milroy, and R.E. Cameron. The effects of molecular weight and porosity on the degradation and drug release from polyglycolide. Int.J. Pharm. 2004;282(1-2):19-34.
287. Farrar, D.F. and R.K. Gillson. Hydrolytic degradation of polyglyconate B: The relationship between degradation time, strength and molecular weight. Biomaterials 2002;23(18):3905-3912.
288. Park, T.G. Degradation of poly(d,l-lactic acid) microspheres: Effect of molecular weight.J. Control. Release 1994;30(2):161-173.
289. Saha, S.K. and H. Tsuji. Effects of molecular weight and small amounts of d-lactide units on hydrolytic degradation of poly(l-lactic acid)s. Polym. Degrad. Stab. 2006;91(8):1665-1673.
290. Yoon, J.-S., H.-J. Jin, I.-J. Chin, C. Kim, and M.-N. Kim. Theoretical prediction of weight loss and molecular weight during random chain scission degradation of polymers. Polymer 1997;38(14):3573-3579.
291. Allen, N.S., M. Edge, M. Mohammadian, and K. Jones. Hydrolytic degradation of poly(ethylene terephthalate): Importance of chain scission versus crystallinity. Eur. Polym.J. 1991;27(12):1373-1378.
292. Chan, C.-K. and I.M. Chu. In vitro degradation of poly(sebacic anhydride-coethylene glycol). Mater. Chem. Phys. 2004;88(1):59-66.
293. Miyajima, M., A. Koshika, J.i. Okada, M. Ikeda, and K. Nishimura. Effect of polymer crystallinity on papaverine release from poly (L-lactic acid) matrix J. Control. Release 1997;49(2-3):207-215.
294. Montaudo, G. and P. Rizzarelli. Synthesis and enzymatic degradation of aliphatic copolyesters. Polym. Degrad. Stab. 2000;70(2):305-314.
295. Schliecker, G., C. Schmidt, S. Fuchs, R. Wombacher, and T. Kissel. Hydrolytic degradation of poly(lactide-co-glycolide) films: Effect of oligomers on degradation rate and crystallinity. Int.J. Pharm. 2003;266(1-2):39-49.
296. Tsuji, H. and S. Miyauchi. Poly(L-lactide): VI. Effects of crystallinity on enzymatic hydrolysis of poly(L-lactide) without free amorphous region. Polym. Degrad. Stab. 2001;71(3):415-424.
297. Zilberman, M. Dexamethasone loaded bioresorbable films used in medical support devices: Structure, degradation, crystallinity and drug release. Acta Biomater. 2005;1(6):615-624.
298. Hurrell, S. and R.E. Cameron. The effect of initial polymer morphology on the degradation and drug release from polyglycolide. Biomaterials 2002;23 (11):2401-2409.
299. Klose, D., F. Siepmann, K. Elkharraz, and J. Siepmann. PLGA-based drug delivery systems: Importance of the type of drug and device geometry. Int.J. Pharm. 2008;354(1-2):95-103.
300. Shen, E., M.J. Kipper, B. Dziadul, M.K. Lim, and B. Narasimhan. Mechanistic relationships between polymer microstructure and drug release kinetics in bioerodible polyanhydrides J. Control. Release 2002;82(1):115-125.
301. Witt, C., K. Mä der, and T. Kissel. The degradation, swelling and erosion properties of biodegradable implants prepared by extrusion or compression moulding of poly(lactide-co-glycolide) and ABA triblock copolymers. Biomaterials 2000;21(9):931-938.
302. Andrianov, A.K. and A. Marin. Degradation of polyaminophosphazenes: Effects of hydrolytic environment and polymer processing. Biomacromolecules 2006;7 (5):1581-1586.
303. Gogolewski, S., M. Jovanovic, S.M. Perren, J.G. Dillon, and M.K. Hughes. The effect of melt-processing on the degradation of selected polyhydroxyacids: Polylactides, polyhydroxybutyrate, and polyhydroxybutyrate-co-valerates. Polym. Degrad. Stab. 1993;40(3):313-322.
304. Reich, G. Ultrasound-induced degradation of PLA and PLGA during microsphere processing: Influence of formulation variables. Eur.J. Pharm. Biopharm. 1998;45 (2):165-171.
305. Söderga° rd, A. and M. Stolt. Properties of lactic acid based polymers and their correlation with composition. Prog. Polym. Sci. 2002;27(6):1123-1163.
306. Yasin, M., S.J. Holland, and B.J. Tighe. Polymers for biodegradable medical devices: V. Hydroxybutyrate-hydroxyvalerate copolymers: Effects of polymer processing on hydrolytic degradation. Biomaterials 1990;11(7):451-454.
307. Johnson, L.R. and N.H. Stoller. Rationale for the use of Atridox therapy for managing periodontal patients. Compend. Contin. Edu. Dent. 1999;20(4 Suppl): 19-25; quiz 35.
308. Page, R.C. The microbiological case for adjunctive therapy for periodontitis.J. Int. Acad. Periodontol. 2004;6(4 Suppl):143-149.
309. Southard, G.L., R.L. Dunn, and S. Garrett. The drug delivery and biomaterial attributes of the ATRIGEL technology in the treatment of periodontal disease. Expert. Opin. Investig. Drugs 1998;7(9):1483-1491.
310. Jonat, W. Goserelin (Zoladex)-its role in early breast cancer in pre-and perimenopausal women. Br.J. Cancer.2001;85(Suppl 2):1-5.
311. Mitchell, H. Goserelin ('Zoladex')-offering patients more choice in early breast cancer. Eur.J. Oncol. Nurs. 2004;8(Suppl 2):S95-103.
312. Schlaff, W.D. Extending the treatment boundaries: Zoladex and add-back. Int.J. Gynaecol. Obstet. 1999;64(Suppl 1):S25-31.
313. Tsukagoshi, S. A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)- outline of pre-clinical and clinical studies. Gan To Kagaku Ryoho. 2002;29 (9):1675-1687.
314. Agarwal, N., D. Fletcher, and J. Ward. Obesity and treatment of prostate cancer: What is the right dose of Lupron Depot? Clin. Cancer Res. 2007;13(13):4027.
315. Dlugi, A.M., J.D. Miller, and J. Knittle. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebocontrolled, double-blind study. Lupron Study Group. Fertil Steril. 1990;54 (3):419-427.
316. Machluf, M., A. Orsola, and A. Atala. Controlled release of therapeutic agents: Slow delivery and cell encapsulation. World J. Urol. 2000;18(1):80-83.
317. Anonymus. Product Portfolio. Available from: http://www.takeda.com/abouttakeda/ product-portfolio/article_73.html; 2009.
318. Richtering, W., J. Siepmann, and F. Siepmann. Microparticles used as drug delivery systems. In Smart Colloidal Materials. Springer Berlin/Heidelberg, 2006, pp. 15-21.
319. Anonymus, Eligard. Tiny implant fights prostate cancer. Nursing 2002;32(5):18.
320. Sartor, O. Eligard: Leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61(2 Suppl 1):25-31.
321. Sartor, O. Eligards 6: A new form of treatment for prostate cancer. Eur. Urol. Supple. 2006;5(18):905-910.
322. Flogstad, A.K., J. Halse, S. Bakke, I. Lancranjan, P. Marbach, C. Bruns, and J. Jervell. Sandostatin LAR in acromegalic patients: Long-term treatment.J. Clin. Endocrinol. Metab. 1997;82(1):23-28.
323. Grass, P., P. Marbach, C. Bruns, and I. Lancranjan. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationships. Metabolism 1996;45(8 Suppl 1):27-30.
324. Heijckmann, C.A., P.P. Menheere, J.P. Sels, E.A. Beuls, and B.H. Wolffenbuttel. Clinical experience with Sandostatin LAR in patients with acromegaly. Neth.J. Med. 2001;59(6):286-291.
325. Lancranjan, I., C. Bruns, P. Grass, P. Jaquet, J. Jervell, P. Kendall-Taylor, S.W. Lamberts, P. Marbach, H. Orskov, G. Pagani, M. Sheppard, and L. Simionescu. Sandostatin LAR: A promising therapeutic tool in the management of acromegalic patients. Metabolism 1996;45(8 Suppl 1):67-71.
326. Cook, D.M., B.M. Biller,M.L. Vance, A.R. Hoffman, L.S. Phillips, K.M. Ford, D.P. Benziger, A. Illeperuma, S.L. Blethen, K.M. Attie, L.N. Dao, J.D. Reimann, and P.J. Fielder. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.J. Clin. Endocrinol. Metab. 2002;87(10):4508-4514.
327. Silverman, B.L., S.L. Blethen, E.O. Reiter, K.M. Attie, R.B. Neuwirth, and K.M. Ford. A long-acting human growth hormone (Nutropin Depot): Efficacy and safety following two years of treatment in children with growth hormone deficiency.J. Pediatr. Endocrinol. Metab. 2002;15(Suppl 2):715-722.
328. Anonymus. Gliadel wafers for treatment of brain tumors. Med. Lett. Drugs Ther. 1998;40(1035):92.
329. Attenello, F.J., D. Mukherjee, G. Datoo, M.J. McGirt, E. Bohan, J.D. Weingart, A. Olivi, A. Quinones-Hinojosa, and H. Brem. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience. Ann. Surg. Oncol. 2008;15(10):2887-2893.
330. Brem, H. and P. Gabikian. Biodegradable polymer implants to treat brain tumors.J. Control. Release 2001;74(1-3):63-67.
331. Perry, J., A. Chambers, K. Spithoff, and N. Laperriere. Gliadel wafers in the treatment of malignant glioma: A systematic review. Curr. Oncol. 2007;14 (5):189-194.
332. Wang, C.C., J. Li, C.S. Teo, and T. Lee. The delivery of BCNU to brain tumors.J. Control. Release 1999;61(1-2):21-41.
333. Li, L.C., J. Deng, and D. Stephens. Polyanhydride implant for antibiotic delivery-from the bench to the clinic. Adv. Drug. Deliv. Rev. 2002;54(7):963-986.
334. Harrison, T.S. and K.L. Goa. Long-acting risperidone: A review of its use in schizophrenia. CNS Drugs 2004;18(2):113-132.
335. Keith, S. Use of long-acting risperidone in psychiatric disorders: Focus on efficacy, safety and cost-effectiveness. Expert Rev. Neurother. 2009;9(1):9-31.
336. Knox, E.D. and G.L. Stimmel. Clinical review of a long-acting, injectable formulation of risperidone. Clin. Ther. 2004;26(12):1994-2002.
337. Lessem, J. and A. Hanlon. A post-marketing study of 2805 patients treated for periodontal disease with Arestin.J. Int. Acad. Periodontol. 2004;6(4 Suppl): 150-153.
338. Van Dyke, T.E., S. Offenbacher, L. Braswell, and J. Lessem. Enhancing the value of scaling and root-planing: Arestin clinical trial results.J. Int. Acad. Periodontol. 2002;4(3):72-76.
339. Anonymus. Capronor. Hypotenuse 1985;2-5.
340. Darney, P.D., C.M. Klaisle, S.E. Monroe, C.E. Cook, N.R. Phillips, and A. Schindler. Evaluation of a 1-year levonorgestrel-releasing contraceptive implant: Side effects, release rates, and biodegradability. Fertil. Steril. 1992;58 (1):137-143.
341. Darney, P.D., S.E. Monroe, C.M. Klaisle, and A. Alvarado. Clinical evaluation of the Capronor contraceptive implant: Preliminary report. Am.J. Obstet. Gynecol. 1989;160(5 Pt 2):1292-1295.
342. Gettig, J., J.P. Cummings, and K. Matuszewski.H.P. Acthar gel and cosyntropin review: Clinical and financial implications.P. T. 2009;34(5):250-257.
343. Miller, M.A. and H.E. Bass. Effect of Acthar-c (ACTH) in sarcoidosis. Ann. Intern. Med. 1952;37(4):776-784.
344. Kim, S.C., D.W. Kim, Y.H. Shim, J.S. Bang, H.S. Oh, S. Wan Kim, and M.H. Seo. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy.J. Control. Release 2001;72(1-3):191-202.
345. Kim, T.Y.,D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim,D.S. Heo,N.K. Kim, and Y.J. Bang. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004;10(11):3708-3716.
346. Lee, K.S., H.C. Chung, S.A. Im, Y.H. Park, C.S. Kim, S.B. Kim, S.Y. Rha, M.Y. Lee, and J. Ro. Multicenter phase II trial of Genexol-PM, a Cremophorfree, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008;108(2):241-250.
347. Lim, W.T., E.H. Tan, C.K. Toh, S.W. Hee, S.S. Leong, P.C. Ang, N.S. Wong, and B. Chowbay. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol(R)-PM) in patients with solid tumors. Ann. Oncol. 2009;21 (2):382-388.
348. Fu, Q., J. Sun, W. Zhang, X. Sui, Z. Yan, and Z. He. Nanoparticle albumin-bound (nab) technology is a promising method for anti-cancer drug delivery. Recent Pat. Anticancer Drug Discov. 2009;4(3):262-272.
349. Green, M.R., G.M. Manikhas, S. Orlov, B. Afanasyev, A.M. Makhson, P. Bhar, and M.J. Hawkins. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006;17(8):1263-1268.
350. Henderson, I.C. and V. Bhatia. Nab-paclitaxel for breast cancer: A new formulation with an improved safety profile and greater efficacy. Expert Rev. Anticancer Ther. 2007;7(7):919-943.
351. McIlwain, C., S.J. Enna, and B.B. David. Abraxane. In xPharm: The Comprehensive Pharmacology Reference. Elsevier: New York, 2008, pp. 1-5.
352. Miele, E., G.P. Spinelli, F. Tomao, and S. Tomao. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int.J. Nanomed. 2009;4:99-105.
353. Anonymus. Dabur pharma introduces Nanoxel in India. Available from http:// www.daburpharma.com/pdf/nanoinindia.pdf, 2007.
354. Krishnan, G.S. Big problem, nano solution. Businessworld 2007;44:1-2.
355. Cirkel, U., H. Ochs, and H.P. Schneider. A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis. Eur.J. Obstet. Gynecol. Reprod. Biol. 1995;59(1):61-69.
356. Dal Prato, L., A. Borini, M. Cattoli, M.A. Bonu, E. Sereni, and C. Flamigni. GnRH analogs: Depot versus short formulations. Eur.J. Obstet. Gynecol. Reprod. Biol. 2004;115(Suppl 1):S40-S43.
357. Filicori, M., C. Flamigni, G. Cognigni, P. Dellai, R. Arnone, A. Falbo, and M. Capelli. Comparison of the suppressive capacity of different depot gonadotropinreleasing hormone analogs in women.J. Clin. Endocrinol. Metab. 1993;77(1): 130-133.
358. Heger, S., C.J. Partsch, and W.G. Sippell. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function.J. Clin. Endocrinol. Metab. 1999;84(12):4583-4590.
359. Schneider, F., B. Heleil, H. Alm, H. Torner, F. Becker, T. Viergutz, G. Nurnberg, and W. Kanitz. Endocrine, morphological, and cytological effects of a depot GnRH agonist in bovine. Anim. Reprod. Sci. 2006;92(1-2):9-28.
360. Anonymus. Naltrexone (vivitrol)-a once-monthly injection for alcoholism. Med. Lett. Drugs Ther. 2006;48(1240):63-64.
361. Johnson, B.A. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther. Clin. Risk Manag. 2007;3(5):741-749.
362. Mannelli, P., K. Peindl, P.S. Masand, and A.A. Patkar. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev. Neurother. 2007;7 (10):1265-1277.
363. Aro, J., M. Ruutu, H. Juusela, E. Hansson, and J. Permi. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group. Ann. Chir. Gynaecol. Suppl. 1993;206:5-8.
364. Schliecker, G., C. Schmidt, S. Fuchs, A. Ehinger, J. Sandow, and T. Kissel. In vitro and in vivo correlation of buserelin release from biodegradable implants using statistical moment analysis.J. Control. Release 2004;94(1):25-37.
365. Waxman, J., J. Sandow, H. Thomas, N. James, and G. Williams. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer. Cancer Chemother. Pharmacol. 1989;25(3):219-220.
366. Waxman, J.H., J. Sandow, P. Abel, N. Farah, E.P. O'Donoghue, J. Fleming, J. Cox, K. Sikora, and G. Williams. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Acta Endocrinol. (Copenh.) 1989;120(3):315-318.
367. Waxman, J.H., J. Sandow, A. Man, M.J. Barnett, W.F. Hendry, G.M. Besser, R.T. Oliver, and P.J. Magill. The first clinical use of depot buserelin for advanced prostatic carcinoma. Cancer Chemother. Pharmacol. 1986;18(2):174-175.
368. Anonymus. Abarelix: Abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R.
369. Drugs R. D 2003;4(3):161-166.
370. Hogle, W.P. Abarelix (plenaxis). Clin.J. Oncol. Nurs. 2004;8(6):663-665.
371. Reddy, G.K. Abarelix (Plenaxis): A gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. Clin. Prostate Cancer 2004;2(4):209-211.
372. Angelova, N. and D. Hunkeler. Rationalizing the design of polymeric biomaterials. Trends Biotechnol. 1999;17:409-421.
373. Kohn, J. and R. Langer. Bioresorbable and bioerodible materials in biomaterials science. In An Introduction to Materials in Medicine. Ratner, B.D., A.S. Hoffman, F.J. Schoen, and J.E. Lemons (Eds.). Academic Press: New York, 1996, pp. 64-72.
374. Pillai, O. and R. Panchagnula. Polymers in drug delivery. Curr. Opin. Chem. Biol. 2001;5:447-451.